Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02286154 · ClinicalTrials.gov registry record · NA

Therapeutic Response Evaluation and Adherence Trial (TREAT)

A NA study of Anemia, Sickle Cell, sponsored by Children's Hospital Medical Center, Cincinnati.

Active
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT02286154 is a NA study of Anemia, Sickle Cell that is active but no longer recruiting, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 150 participants, above the 109-participant average among 17 other Anemia, Sickle Cell trials with a reported enrollment target (38% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02286154, a NA study of Anemia, Sickle Cell, is active but no longer recruiting, sponsored by Children's Hospital Medical Center, Cincinnati.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

The primary objectives of this prospective study of hydroxyurea for children with sickle cell anemia are 1) Develop and prospectively evaluate a population pharmacokinetic/pharmacodynamics model to predict the maximum tolerated dose (MTD); 2) Identify urine biomarkers of hydroxyurea adherence using a novel metabolomics approach; 3) Identify pharmacogenomics modifiers of hydroxyurea MTD; and 4) Longitudinal monitoring of the effect of hydroxyurea upon organ function and quality of life.

Conditions Studied

Interventions

  • DRUG Hydroxyurea

Study Locations (1)

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2014-10
Est. Completion 2026-12
Phase NA

What the Registry Record Tells You About NCT02286154

The ClinicalTrials.gov registry entry for NCT02286154 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 109-participant average among 17 other Anemia, Sickle Cell trials with a reported enrollment target (38% higher). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Anemia, Sickle Cell appearing as the primary indexed condition, and to 1 intervention - of which Hydroxyurea is the first listed.

NCT02286154 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT02286154 about?

NCT02286154 is a clinical study titled "Therapeutic Response Evaluation and Adherence Trial (TREAT)". The primary objectives of this prospective study of hydroxyurea for children with sickle cell anemia are 1) Develop and prospectively evaluate a population pharmacokinetic/pharmacodynamics model to predict the maximum tolerated dose (MTD); 2) Identify urine biomarkers of hydroxyurea adherence using ...

What is the current status of trial NCT02286154?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2014-10. Estimated completion is 2026-12.

What conditions does trial NCT02286154 study?

This clinical trial studies the following conditions: Anemia, Sickle Cell.

What interventions are being tested in trial NCT02286154?

The interventions under investigation include: Hydroxyurea (DRUG).

Who is sponsoring clinical trial NCT02286154?

This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02286154 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anemia, Sickle Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.